Introduction
Immune responses within the tumor microenvironment are increasingly implicated as determining factor in tumor progression and aggressiveness. Understanding these responses has allowed investigators to use immune markers to stratify prognosis of colorectal and ovarian cancer patients (1, 2). High levels of intratumoral effector memory cells in colorectal cancer and CD3+ T cells in ovarian cancer are associated with prolonged survival.
Published studies investigating immune markers as prognosticators in non-small cell lung cancer (NSCLC) are heterogeneous in histology (adenocarcinoma, squamous cell, and large cell) and stage (I-IV). In this review, we have identified prognostic immune markers in the tumor microenvironment and peripheral blood, as well as tumor expression of immune genes. The immune genes, from 17 published NSCLC gene profiling studies, were evaluated for prognostic significance in the NIH Director's Challenge microarray (3), the largest multi-center gene profiling study to date.
Prognostic Immune Cells

Tumor-Infiltrating Lymphocytes (TILs)
The interaction between tumor and immune cells in the tumor microenvironment is influenced by the type of immune cells (CD8+, CD4+, CD20+, and FoxP3+ -see Table 1 ), their density (as counted microscopically), and location (tumor nest and stroma) (4) infiltration and survival (6) (7) (8) (9) (10) . Pertinent to NSCLC patients is the fact that CD8+ T-cell predominance is a characteristic of smoking-related chronic obstructive pulmonary disease (11), and they are thought to drive the progression of emphysema (12). In mouse models, activation of CD8+ T cells are impaired in the presence of cigarette smoke (13, 14), perhaps explaining this finding in NSCLC patients. In fact, studies that report correlation between CD8+ TIL and prognosis contradict each other (15, 16) . Ruffini et al. demonstrate in their investigation of 1290 NSCLC tumors that TILs, mostly CD8+, were associated with prolonged survival but only in a subset of squamous cell carcinomas (n=549) (15) . This is contrasted by Wakabayashi et al., who correlate tumoral CD8+ and shorter overall survival in NSCLC, especially in adenocarcinoma (16) . Examining the functional significance of CD8+ T-cells, Trojan et al. analyzed mRNA ratio of IFN-γ to CD8, where IFN-γ is an effector cytokine secreted by cytotoxic T cells, specifically in peri-tumoral areas and within tumor nests. While the number of peritumoral CD8+ T cells correlated with the IFN-γ/CD8 ratio, this association was not observed intra-tumorally (8) . This suggests that while the CD8+ T-cells are able to infiltrate the tumor, they are not able to mount a robust anti-tumor response once within the tumor nest.
7 urinary PGE-M, the major metabolite of PGE 2 , was proposed as a biomarker to predict response to COX-2 inhibitors in NSCLC patients (22 
Tumor-Associated Macrophages (TAMs)
TAMs demonstrate both pro-and anti-tumor effects in the tumor microenvironment (24) . Anti-tumor TAMs in NSCLC are of the M1 phenotype and accumulate intra-tumorally while pro-tumor TAMs of the M2 phenotype accumulate in the stroma and express IL-8, IL-10, and triggering receptor expressed on myeloid cells (TREM-1). IL-8 is an angiogenic factor, and TAM's angiogenic role in NSCLC has been shown by correlating macrophage density with intra-tumor microvessel counts and poor patient outcomes (25) . By performing RT-PCR for IL-8 in resected specimens, the study concludes that TAMs lead to poor patient outcome by their angiogenic role through IL-8 production. IL-10 is an immunosuppressive cytokine, and its expression by TAM has been observed more commonly in stages II/III/IV, thus correlating with decreased OS (26) . TAM expression of TREM-1, which can initiate and amplify an inflammatory response, is increased in malignant pleural effusions of NSCLC Depletion of these N1 neutrophils resulted in increased tumor growth.
Peripheral Blood Lymphocytes
The universal availability of peripheral blood lymphocyte count has led to its investigation as a prognostic marker in NSCLC. In resected NSCLC patients (n=177; 72% Stages I and II), increasing total lymphocyte counts were associated with lower hazard ratios for death (HR 0.62, CI=0.43-0.9; p=0.012) (35) . The same study further identified neutrophil to lymphocyte ratio (NLR) as a superior predictor of survival compared to pathologic stage (p=0.001) (35) . Specifically, an NLR of >3.81 was found to be a significant predictor of survival in patients with stage I NSCLC. As for the tumor-promoting Tregs, they have been observed at an increased level in the peripheral blood of NSCLC patients compared to normal healthy volunteers (36, 37) . These reports correlate with elevated serum and plasma levels of TGF-β and IL-10, both known promoters of Treg development, in NSCLC patients compared to healthy controls (38, 39) . Peripheral blood levels of Tregs, TGF-β, and IL-10, however, have not been investigated in predicting clinical outcome of NSCLC patients.
Myeloid-Derived Suppressor Cells (MDSCs):
MDSCs represent a heterogeneous population of myeloid cells comprising immature macrophages, granulocytes, and DCs at early stages of differentiation that have pro-tumor effects. MDSCs are mobilized from bone marrow into the peripheral blood by tumor-derived factors and accumulate in the tumor microenvironment, where they exert their pro-tumor effect by inhibiting T cell proliferation and activation (40) . Similar to Tregs, increased levels of MDSCs, marked by CD11b+/CD14-/CD15+/ CD33+, were observed in the peripheral blood of advanced stage NSCLC patients (n = 87) compared to healthy controls (41) . In addition, high levels of MDSCs were associated with decreased levels of CD8+ T cells, further supporting the pro-tumor effect of MDSCs. No study to date, however, has investigated the prognostic significance of MDSCs in the tumor microenvironment of patient samples.
Summary of Prognostic Tumor-Infiltrating Immune Cells
Stromal CD4+ lymphocytes, especially co-localized with CD8+ lymphocytes, stromal CD20+ B lymphocytes, Ti-BALT, and intra-tumoral macrophages (M1) are associated with prolonged survival in NSCLC. In contrast, FoxP3+ Tregs, stromal macrophages (M2), and their associated cytokines -IL-8, IL-10, and TREM-1 -are associated with poor prognosis.
Research. 
Tumor expression and secretion of COX-2 and IL-10, respectively, lead to shorter survival.
These prognostically significant findings are summarized in Figure 1 .
Prognostic Immune Genes
In the large, multi-site, blinded validation study examining lung adenocarcinoma Figure 1) , resulting in a list of 84 genes (Supplementary Table   2 ). 
As shown in
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Significance of Prognostic Immune Genes in the NIH Director's Challenge study
Cox proportional hazards model was used to evaluate the association between DFS and the expression profiles of the 84 identified prognostic immune genes in the Director's Challenge dataset (3). This analysis revealed 17 genes which were significantly associated with recurrence (Table 2) . We employed the Ingenuity Pathway Analysis to examine the networks shared by the 17 genes (Figure 3) . STAT3 was a common signal transduction pathway highlighted in this analysis, which has been implicated in cancer inflammation and immunity (66) . TREM-1 [27] IL-8 [25] [41]
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